Preclinical data from sars-cov-2 mrna vaccine

Preclinical data from sars-cov-2 mrna vaccine


Play all audios:


Access through your institution Buy or subscribe Reflecting the urgency to develop prophylactic approaches against COVID-19, several vaccine candidates have entered clinical trials before


showing efficacy in animal models. In this preprint, Corbett et al. describe a preclinical study evaluating an mRNA vaccine candidate by Moderna. Immunization of mice with mRNA encoding


stabilized prefusion SARS-CoV-2 spike trimers elicited dose-dependent neutralizing antibody and CD8+ T cell responses. Two doses given in prime–boost combination (2 x 1 µg/mouse) protected


mice against infection of the nasal mucosa and lungs after challenge with mouse-adapted SARS-CoV-2. Importantly, there was no indication of enhanced immunopathology in animals that received


sub-protective doses. A phase III efficacy trial in humans (using a single 100 µg dose regimen) is set to start in July. This is a preview of subscription content, access via your


institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel


any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink *


Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional


subscriptions * Read our FAQs * Contact customer support REFERENCES ORIGINAL ARTICLE * Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness.


Preprint at _bioRxiv_ https://doi.org/10.1101/2020.06.11.145920 (2020) Article  PubMed  PubMed Central  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *


Sinai Immunology Review Project, Icahn School of Medicine at Mount Sinai, New York, NY, USA Nicolas Vabret Authors * Nicolas Vabret View author publications You can also search for this


author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Nicolas Vabret. ETHICS DECLARATIONS COMPETING INTERESTS The author declares no competing interests. RIGHTS AND


PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Vabret, N. Preclinical data from SARS-CoV-2 mRNA vaccine. _Nat Rev Immunol_ 20, 461 (2020).


https://doi.org/10.1038/s41577-020-0377-3 Download citation * Published: 22 June 2020 * Issue Date: August 2020 * DOI: https://doi.org/10.1038/s41577-020-0377-3 SHARE THIS ARTICLE Anyone you


share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the


Springer Nature SharedIt content-sharing initiative